Literature DB >> 17072932

Synthesis, solution thermodynamics, and X-ray study of CuII [12]metallacrown-4 with GABA hydroxamic acid: an unprecedented crystal structure of a [12]MC-4 with a gamma-aminohydroxamate.

Matteo Tegoni1, Luca Ferretti, Francesco Sansone, Maurizio Remelli, Valerio Bertolasi, Francesco Dallavalle.   

Abstract

The solution equilibria of gamma-aminobutanehydroxamic acid (GABAha) with H+ and Cu2+ were investigated by potentiometry, titration calorimetry, spectrophotometry, NMR spectroscopy, and ESI-MS. The thermodynamic parameters of the CuII [12]metallacrown-4 obtained for GABAha were compared with those of the corresponding complexes of (S)-alpha-Alaha and beta-Alaha. The stability (-DeltaG0) sequence was beta-Alaha>>alpha-Alaha>GABAha, whereas the order of formation enthalpies (-DeltaH0) was beta-Alaha>>GABAha>alpha-Alaha. These data were interpreted on the basis of the dimensions of the chelate rings and the planarity of the metallamacrocycles. The CuII [12]metallacrown-4 ([12]MC-4) complex of GABAha was isolated and its crystal structure, which is the first reported for a [12]MC-4 of a gamma-aminohydroxamic acid, fully supports the structural features interpreted from the thermodynamic data.

Entities:  

Year:  2007        PMID: 17072932     DOI: 10.1002/chem.200601035

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  Synthesis and crystal structure of a penta-copper(II) 12-metallacrown-4: cis-di-aqua-tetra-kis-(di-methyl-formamide-κO)manganese(II) tetra-kis-(μ3-N,2-dioxido-benzene-1-carboximidate)penta-copper(II) di-methyl-formamide monosolvate.

Authors:  Gerard P Van Trieste Iii; Matthias Zeller; Curtis M Zaleski
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-04-30

Review 2.  Diversity in the Interaction of Amino Acid- and Peptide-Based Hydroxamic Acids with Some Platinum Group Metals in Solution.

Authors:  Linda Bíró; Péter Buglyó; Etelka Farkas
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.